A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib monotherapy in RAS Mutant Metastatic Colorectal Cancer

Trial Profile

A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib monotherapy in RAS Mutant Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms PROSPECT-R
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Aug 2017 Results (n=27) of DCE-MRI and ctDNA analysis published in the Gut
    • 30 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top